CPX-351 with venetoclax in R/R AML: results of a Phase Ib study

Combining venetoclax with CPX-351 for AMLПодробнее

Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AMLПодробнее

CPX-351 vs. HMA plus venetoclax in the treatment of patients with AMLПодробнее

CPX-351 plus venetoclax in patients with newly-diagnosed high-risk AMLПодробнее

Safety and efficacy of CPX-351 in newly diagnosed AML patients under the age of 60Подробнее

HMA in combination with venetoclax and magrolimab in the treatment of AMLПодробнее

Improved understanding of CPX-351 in AML: impact of HCT & final EAP resultsПодробнее

CPX-351 for Secondary AMLПодробнее

Role of CPX-351 in Acute Myeloid LeukemiaПодробнее

CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?Подробнее

Liposomal daunorubicin and cytarabine in R/R ALLПодробнее

What does real-world data tell us about frontline therapy with CPX-351 vs Ven + Aza?Подробнее

CPX-351 in Newly Diagnosed Secondary AMLПодробнее

Evaluating CPX-351 against 7+3 in older newly diagnosed AMLПодробнее

CPX-351: liposomal daunorubicin/cytarabine for AMLПодробнее

Analyzing the cost-effectiveness of CPX-351 in patients with AMLПодробнее

Cardiotoxicity of CPX-351 vs 7+3 chemotherapy in patients with untreated high-risk AMLПодробнее

Outcomes of patients with de-novo vs secondary AML treated with CPX-351Подробнее

CPX-351 and gemtuzumab ozogamicin in R/R AML and MDSПодробнее